Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Rhea-AI Summary
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of December 31, 2025. The company confirms 235,670,864 total shares and a total gross of voting rights: 235,670,864. The total net of voting rights (excluding shares without voting rights) is 235,596,284. This document supersedes the prior publication of January 5, 2026 to reflect earlier exercises of employee stock plan instruments and warrants from a previous financing.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DBVT declined 5.02%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $45M from the company's valuation, bringing the market cap to $854M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DBVT was modestly higher (0.06%) while peers were mixed: CADL up 1.6%, OMER down 8.57%, ANNX down 2.42%, CAPR down 8.31%, NGNE down 6.08%, suggesting stock-specific trading rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Liquidity contract update | Neutral | +8.2% | Reported liquidity contract share and cash balances and trading activity. |
| Jan 05 | Share/voting update | Neutral | -10.8% | Disclosed total shares and gross/net voting rights as of Dec 31, 2025. |
| Dec 16 | Phase 3 topline data | Positive | -1.7% | Positive Phase 3 VITESSE topline results for VIASKIN Peanut patch. |
| Dec 02 | Share/voting update | Neutral | -0.6% | Updated total shares and voting rights as of November 30, 2025. |
| Nov 11 | Clinical trial progress | Positive | -1.8% | Last patient visit completed in VITESSE Phase 3 VIASKIN Peanut trial. |
Positive clinical trial milestones have previously coincided with negative 24-hour price reactions, while routine share and voting-rights disclosures have had modest or mixed impact.
Over the past months, DBVT combined administrative disclosures with major clinical progress. Regular reports on total shares and voting rights as of November 30, 2025 and December 31, 2025 updated investors on capital structure. Clinically, the company completed last patient visits in the VITESSE Phase 3 trial on Nov 11, 2025 and later announced positive topline results on Dec 16, 2025, yet both saw slightly negative next-day moves. A half-year liquidity contract report on Jan 7, 2026 coincided with a strong positive reaction of 8.18%.
Market Pulse Summary
The stock moved -5.0% in the session following this news. A negative reaction despite neutral share-count news fits prior patterns where even positive clinical milestones saw selling. The company reported 235,670,864 shares and net voting rights of 235,596,284 as of year-end, superseding an earlier filing. Similar updates on voting rights in late 2025 coincided with modest declines. Given this backdrop and existing insider activity and financing history, sharp downside moves on administrative disclosures could reflect sensitivity to perceived dilution risk or capital-structure changes.
Key Terms
isin financial
AI-generated analysis. Not financial advice.
Information Regarding the Total number of Voting Rights and
Total Number of Shares of the Company as of December 31, 2025
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
| Notice: This document supersedes and replaces the information previously published on January 5, 2026, to account for the earlier exercise of various securities instruments, in connection with the Company’s employee stock ownership plans and warrants from a previous financing transaction. |
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 12/31/2025 | 235,670,864 | Total gross of voting rights: 235,670,864 |
| Total net* of voting rights: 235,596,284 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Attachment
FAQ
What is the total number of DBVT shares as of December 31, 2025?
What are DBVT's total gross and net voting rights as of 12/31/2025?
Why was the DBVT share and voting rights notice updated on January 12, 2026?
Which market and ISIN correspond to DBVT in this disclosure?
How is the "total net of voting rights" defined for DBVT?
